Bio-Path Holdings Presents Data From Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients

GlobeNewswireJun 3 07:00 ET

What's Going On With Bio-Path Stock?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination w

BenzingaJun 3 10:08 ET

Express News | Bio-Path Shares Are Trading Higher After the Company Announced the Presentation of Data From Its Ongoing Phase 2 Combination Study of Prexigebersen for the Treatment of Acute Myeloid Leukemia at the ASCO Annual Meeting

BenzingaJun 3 10:07 ET

Nasdaq Surges 150 Points; US Manufacturing PMI Rises In May

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 150 points on Monday.The Dow traded down 0.07% to 38,657.77 while the NASDAQ climbed 0.92% to 16,888.59. The S&P

BenzingaJun 3 09:54 ET

Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May

US stocks look set to open slightly higher in Monday's trading session as investors await key manufacturing data coming out later in the morning. The Dow Jones Industrial Average futures were off 0.03

MT NewswiresJun 3 09:19 ET

Bio-Path Holdings (BPTH) Stock Surges 62% on Promising Phase 2 Data

Bio-Path Holdings, Inc. (NASDAQ: BPTH) experienced a remarkable surge in premarket trading on Monday, following a substantial climb of nearly 7% on Friday. The stock soared an astounding 62%, reaching a high of $3.38 during early premarket hours, compared to its Friday price of $1.93. This surge was accompanied by a notable trading volume of ...

Stocks TelegraphJun 3 08:55 ET